Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the RNA Targeting Small Molecule Drug Discovery Market From 2025 to 2029?

In recent years, the market size for RNA targeting small molecule drug discovery has seen rapid expansion. It is projected to rise from a worth of $1.76 billion in 2024 to $2.13 billion by the end of 2025, recording a compound annual growth rate (CAGR) of 20.8%. This growth during the historical period is due to factors such as a greater comprehension of disease genetics, advances in genomic and proteomic discoveries, challenges in drug resistance, investment boosts in biotech and pharmaceutical research, and the emergence of RNA therapeutics.

The market for RNA targeting small molecule drug discovery is projected to witness a significant surge in the foreseeable future. Its valuation is anticipated to reach $4.85 billion by 2029, growing at a compound annual growth rate (CAGR) of 22.9%. This growth in the projected timeframe may be due to factors such as the broadening scope of RNA epigenetics research, RNA-seq, and functional genomics, the incorporation of artificial intelligence (AI), emphasis on patient-oriented approaches, and the use of exosomes for drug delivery. Other key market trends in this period are expected to be the development of RNA editing methods, advancements in CRISPR technology, tech-based innovations, progress in RNA biology, and the application of RNA targeting in treating neurodegenerative diseases.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

What Elements Are Contributing To Growth In The RNA Targeting Small Molecule Drug Discovery Market?

The escalating incidence of cancer, genetic abnormalities, and viral infections is anticipated to drive the expansion of the RNA-targeted small-molecule drug discovery market. Cancer encompasses a range of conditions typified by unrestrained cell proliferation within the body, while viral infections are caused by minuscule infectious elements that can only replicate within the cells of living organisms. RNA-based drug discovery proves useful in combating these diseases, as they are fundamentally associated with gene-related issues and dysfunctional genetic material, which can be remedied using medications formulated via RNA targeting methods. As an illustration, the World Health Organization, a Swiss intergovernmental entity, reported in February 2024 that diseases like lung cancer, with 2.5 million new cases (12.4%), breast cancer in women (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%) were prevalent across the globe in 2022, with a total of 20 million cancer cases and 9.7 million deaths. It is projected that by 2050, the number of new cancer cases will increase by 77%, surpassing 35 million per year. Thus, the growing occurrence of cancer, genetic anomalies, and viral infections propels the advancement of the RNA-targeted small-molecule drug discovery market.

Which Segments Are Detailed In The Global RNA Targeting Small Molecule Drug Discovery Market Report?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies

3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Which Emerging Trends And Strategic Shifts Are Shaping The RNA Targeting Small Molecule Drug Discovery Market?

Top-tier firms in the repsules industry are prioritizing the creation of ground-breaking items, such as unique pharmaceutical solutions that augment drug delivery, boost patient adherence, and heighten therapeutic effectiveness. These innovative pharmaceutical commodities are fresh and different drugs or drug formulations, showing considerable variation from existing therapies. They may offer distinct active ingredients, a new mix of medications, or up-to-date delivery systems crafted to increase efficiency, safety, and patient compliance. For example, in January 2023, Lupin Limited, a firm from India in the pharmaceutical sector, introduced DIFIZMA, a new fixed-dose triple drug combination for the treatment of poorly controlled asthma. This combination features Indacaterol, a long-lasting beta-agonist; Glycopyrronium, a long-lasting muscarinic receptor antagonist; and Mometasone Furoate, an inhaled corticosteroid. Working together, these components enhance lung performance and give superior symptom management. Also, DIFIZMA contributes to a reduction in the frequency of asthma flare-ups, thereby improving patient’s overall life quality and mitigating the hospitalization risk.

Who Are The Key Contributors To Growth In The RNA Targeting Small Molecule Drug Discovery Market?

Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Which Region Is Projected To Lead The RNA Targeting Small Molecule Drug Discovery Market By 2025?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model